PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials

By  

PIGMENT CELL & MELANOMA RESEARCH, Vol. 28, Iss. 3, 2015-05 ,pp. : 245-253

John Wiley & Sons Inc

Access to resources Recommend Favorite

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

By Šmahel Michal  

International Journal of Molecular Sciences, Vol. 18, Iss. 6, 2017-06 ,pp. : 1331-1331

MDPI

Access to resources Recommend Favorite

Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice

By Rom-Jurek Eva-Maria   Kirchhammer Nicole   Ugocsai Peter   Ortmann Olaf   Wege Anja K.   Brockhoff Gero  

International Journal of Molecular Sciences, Vol. 19, Iss. 2, 2018-02 ,pp. : 563-563

MDPI

Access to resources Recommend Favorite

Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients

By Botti Gerardo   Collina Francesca   Scognamiglio Giosuè   Rao Federica   Peluso Valentina   De Cecio Rossella   Piezzo Michela   Landi Gabriella   De Laurentiis Michelino   Cantile Monica   Di Bonito Maurizio  

International Journal of Molecular Sciences, Vol. 18, Iss. 2, 2017-02 ,pp. : 459-459

MDPI

Access to resources Recommend Favorite

A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway Translational Blockade of Immune Checkpoints

By Li Yongshu   Li Fangfei   Jiang Feng   Lv Xiaoqing   Zhang Rongjiang   Lu Aiping   Zhang Ge  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1151-1151

MDPI

Access to resources Recommend Favorite